Quadruple Misfolded Proteins in Older Adults

- Posted by admin in English

In this cohort study, Shama Karanth and colleagues from University of Kentucky, Lexington, investigated quadruple misfolded proteins and other proteinopathy combinations in a cohort of 375 deceased individuals with autopsy data in the University of Kentucky Alzheimer Disease Center (UK-ADC).

At least 3 proteinopathies were observed in 50% of brains.

In addition, quadruple misfolded proteins were associated with severe cognitive impairment at least 12 years before death.

Participants with 3 proteinopathies tended to have poorer global cognition earlier than with the presence of only tau and Aβ and were likely to have higher Braak stages.

Previous studies have reported cognitive decline associated with the presence of mixed pathologies, with study to study differences in methods and proteinopathies, the assessment and inclusion of cerebrovascular pathologies, and hippocampal sclerosis. In the present sample, as in other community based cohorts, FTLD in old age was rare (with an estimated incidence of 8.9 of 100 000 in individuals aged 60 to 69 years; no incidence data are available for older age groups) and was not found in brains of individuals who began follow up with normal cognition.

Individuals with FTLD-TDP-43 with data in the UK-ADC Brain Bank were recruited from a dementia clinic. The scientists excluded 6 individuals with FTLD-TDP-43 in the study; none had the quadruple misfolded proteins phenotype. No discernible overlap in any FTLD feature was observed in these individuals other than presence of TDP-43 proteinopathy, which is now detected in many different neurological diseases outside of the amyotrophic lateral sclerosis–FTLD spectrum.

Cognitive impairment was associated with quadruple misfolded proteins at autopsy, with 89.1% of participants developing dementia and some experiencing profound impairment up to 12 years before death. This finding suggests that quadruple misfolded proteins occur before end stage Alzheimer disease neuropathological change (ie, before high Braak stage).

Consistent with this hypothesis, the mild cognitive impairment to dementia transition was, on average, fastest in the quadruple misfolded proteins group. Estimation of the group cognitive trajectories was aided by the relatively long followup (mean duration of 10.4 years).

These data provide the basis for a novel hypothesis that quadruple misfolded proteins have a more aggressive phenotype from the early stages of the disease rather than accruing additional pathologies only after Alzheimer disease neuropathological change has progressed to high levels. About 10% of these participants died with normal cognition, and previous research has shown quadruple misfolded proteins were present in persons with apparently normal cognition. In the present study, all individuals with quadruple misfolded proteins who had normal cognition at the last visit before death had lower Braak NFT stages (I to III), had no APOEε4 allele, and were predominantly male (4 of 5 participants).

These individuals may represent an early stage of quadruple misfolded proteins, but there are complexities: clinical presentation of proteinopathy combinations may be cohort specific and depend on other currently unknown factors. Older cohorts that survive into advanced old age, like those in the UK-ADC study, may be more likely to experience multiple proteinopathies than younger cohorts. As previously described, APOE appeared to be associated with multiple proteinopathies in this study, particularly those proteinopathy combinations including Aβ plaques. Carriers of APOEε allele not only had increased odds of tau and Aβ, an expected result, but also had higher odds of tau, Aβ, and αsynuclein; tau, Aβ, and TDP-43; and quadruple misfolded proteins.

Unlike previous studies, this study did not find evidence that the ε4 allele was associated with tau or TDP-43 in the absence of Aβ, but the sample size was relatively small. The temporality of protein misfolding may play a clinically important and differentiating role in disease progression.

Autopsy data, although cross-sectional by nature, are compatible with the hypothesis that Aβ aggregates precede, and perhaps stimulate or exacerbate, the widespread misfolding of tau, TDP-43, and α-synuclein. These results suggest that TDP-43 pathology may be associated with poor global cognition.

The presence of multiple proteinopathies, particularly the quadruple misfolded proteins phenotype, appeared to have been associated with the cognitive decline in deceased individuals who participated in a longitudinal community based study at the UK-ADC.

These observations have potentially significant implications for clinical practice and public health, given that strategies to prevent or manage AD dementia may be complicated by the unrecognized presence of multiple additional neuropathologies.

Two epigenetic regulators interfere with healthy aging

- Posted by admin in English

It has long been assumed that lifespan and health are strongly correlated, but although there has been an overall increase in human life expectancy in recent decades, it is too often accompanied by deterioration of health.

A new study published on February 26 in Nature shows the influence of two epigenetic regulators on aging. Scientists led by Jie Yuan from the Chinese Academy of Sciences in Shanghai have studied the BAZ-2 and SET-6 proteins in Caenorhabditis elegans worms, which are orthologs of the human proteins BAZ2B and EHMT1.

Through genome-wide RNA-interference-based screening of genes that regulate behavioral deterioration in aging C. elegans, the researchers identified 59 genes as potential health modulators during aging. Essentially the proteins expressed by these genes, read and write epigenetic signals.

Among these modulators, they found that a neuronal epigenetic reader, BAZ-2, and a neuronal histone SET-6, accelerate the deterioration of the behavior of C. elegans by reducing the mitochondrial function, and repressing the expression of the encoded mitochondrial proteins. in the cell nucleus.

The researchers found that the levels of the two proteins increase with age in C. elegans and mice, which in turn attenuates the expression of genes involved in mitochondrial function.

BAZ-2 and SET-6 are complementary epigenetic mechanisms. SET-6 is an "epigenetic writer" and BAZ-2 is an "epigenetic reader" which recognizes modified histones and recruits transcriptional regulators.

Histones are proteins located in the nucleus of eukaryotic cells. They are the main protein components of chromosomes. They are closely associated with DNA and allow their compaction, but they also modify the expression of proteins by various epigenetic mechanisms known as the "histone code".

enter image description here Source Wikipedia.

How do BAZ-2 and SET-6 accelerate aging? The researchers found that the two proteins bind together to the promoter regions of more than 2,000 genes, and decrease their expression via methylation of histones. Among these target genes are many mitochondrial genes encoded nuclear. By suppressing the expression of these genes, BAZ-2 and SET-6 reduce oxygen consumption and ATP production, and decrease the critical stress responses that maintain mitochondrial proteostasis. The resulting metabolic slowdown discourages the worms from assimilating their food and they mate less.

This mechanism is conserved in the neurons of cultured mice and human cells. What about the orthologs of these epigenetic proteins in humans? A review of the databases shows that expression by human orthologs of the two proteins mentioned above, BAZ2B and EHMT1, increases with age and is positively correlated with the progression of Alzheimer's disease. Researchers have verified that ablation of BAZ-2 mouse ortholog Baz2b attenuates age-dependent body weight gain and prevents cognitive decline in aging mice.

enter image description here While wild-type mice grew fat with age, animals lacking both copies of the epigenetic reader Baz2b stayed trim, indicating improved mitochondrial function. [Yuan et al., Nature, 2020.]

However, it must be asked whether BAZ-2 and SET-6 would rather mediate age-related physiological adaptation, rather than the agents of aging itself. Indeed their action could reflect a mechanism of adaptation to a progressively more hostile biological environment.

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text discusses the relationship between plasma glial fibrillary acidic protein (GFAP), a marker of astrocytic activation, and Alzheimer's disease (Alzheimer's disease) in cognitively unimpaired (CU) older adults. The significance of this topic lies in its potential to provide insights into the early detection and monitoring of Alzheimer's disease, a debilitating neurodegenerative disorder affecting millions worldwide.

Importance:

  1. Early detection and prevention: Identifying prognostic biomarkers like GFAP can facilitate early detection and intervention, potentially slowing or preventing cognitive decline.
  2. Personalized medicine: The observed sex-specific vulnerability highlights the importance of considering individual factors, such as sex, in Alzheimer's disease research and treatment.
  3. Development of targeted therapies: Understanding the relationship between GFAP and Alzheimer's disease can inform the development of novel therapeutic approaches targeting astrocytic activation.

Timeliness:

  1. Advancements in Alzheimer's disease research: The study contributes to the growing field of Alzheimer's disease research, which has seen significant progress in recent years.
  2. Emergence of biomarkers: The identification of plasma GFAP as a prognostic biomarker aligns with the increasing focus on developing reliable biomarkers for Alzheimer's disease.

Relevance:

  1. Clinical implications: The findings have implications for the clinical management of Alzheimer's disease, particularly in the early stages of the disease.
  2. Research applications: The study's results can inform future research on the mechanisms underlying Alzheimer's disease and the development of effective treatments.

Analysis of the Text: Relationship between Items

  1. Plasma GFAP: Elevated plasma GFAP is associated with lower cognitive performance, greater amyloid burden, and faster cognitive decline in CU older adults.
  2. Amyloid burden: Higher amyloid burden is linked to elevated GFAP, suggesting a relationship between astrocytic activation and amyloid accumulation in Alzheimer's disease.
  3. Cognitive decline: Plasma GFAP predicts faster cognitive decline, highlighting its potential as a prognostic biomarker for Alzheimer's disease.
  4. Sex-specific vulnerability: The study reveals stronger associations between GFAP and Alzheimer's disease-related outcomes in females, underscoring the importance of considering sex-specific factors in Alzheimer's disease research.

Usefulness for Disease Management and Drug Discovery:

The study provides valuable insights into the relationship between plasma GFAP and Alzheimer's disease, which can inform the development of novel therapeutic approaches targeting astrocytic activation. Elevated GFAP may serve as a prognostic biomarker for Alzheimer's disease, enabling early detection and intervention. The observed sex-specific vulnerability highlights the need to consider individual factors, such as sex, in Alzheimer's disease research and treatment.

Originality of the Text:

The study provides original information by:

  1. Identifying plasma GFAP as a prognostic biomarker: The study demonstrates the predictive value of plasma GFAP in CU older adults, offering a potential new tool for Alzheimer's disease research and diagnosis.
  2. Highlighting sex-specific vulnerability: The findings emphasize the importance of considering sex-specific factors in Alzheimer's disease research and treatment, which is a relatively unexplored area of study.
  3. Investigating longitudinal associations: The study's longitudinal design allows for a more comprehensive understanding of the relationships between plasma GFAP, cognitive decline, and Alzheimer's disease-related outcomes.

Read the original article on medRxiv

Significance of the Topic: Alzheimer's disease (AD) is a debilitating neurodegenerative disorder with limited therapeutic options, affecting millions worldwide. The failure of the neuronal proteostasis network, a system crucial for preventing toxic protein aggregation, is a fundamental pathological process in AD. This study addresses a critical gap in AD research by exploring a novel therapeutic strategy that targets the molecular chaperones, specifically DNAJB6, which have been identified as deficient in the AD brain.

Importance: The importance of this study lies in its potential to offer a new direction for AD treatment. The current therapeutic landscape for AD is characterized by limited efficacy, and there is an urgent need for innovative approaches. By targeting molecular chaperones, this study may provide a breakthrough in understanding the underlying mechanisms of AD and potentially lead to the development of more effective treatments.

Timeliness: The study's focus on molecular chaperones and the use of engineered exosomes for targeted delivery is timely, given the current advancements in gene therapy and nanotechnology. The increasing understanding of the importance of molecular chaperones in neurodegenerative diseases, including AD, highlights the need for studies like this to investigate their therapeutic potential.

Relevance: This study is highly relevant to AD research, as it aims to evaluate a novel therapeutic approach that targets the root cause of the disease. The use of engineered exosomes for neuron-specific delivery of nucleic acid cargo represents a promising platform for AD treatment. The study's focus on safety, tolerability, and initial proof-of-mechanism data will provide valuable insights into the potential of this therapeutic strategy.

Analysis of the Text:

  • Background: The text provides a concise overview of the current therapeutic landscape for AD and the fundamental pathological process of proteostatic failure. It highlights the importance of molecular chaperones as therapeutic targets and the challenges of delivering large biologics across the blood-brain barrier.
  • Objective: The primary objective of the study is clear, with a focus on evaluating the safety and tolerability of NV-101, an autologous dendritic cell-derived exosome engineered with neuron-targeting peptides and DNAJB6 mRNA. The secondary objectives are also well-defined, focusing on assessing the biological activity of NV-101 through cerebrospinal fluid (CSF) biomarkers.
  • Methods: The study design is described in detail, including the single-center, randomized, double-blind, placebo-controlled, dose-escalation study. The enrollment criteria, randomization ratio, and outcome measures are also outlined.
  • Conclusions: The text concludes by highlighting the significance of this first-in-human study in generating critical safety and initial proof-of-mechanism data for a novel therapeutic strategy aimed at correcting proteostatic failure in AD.

Usefulness for Disease Management or Drug Discovery: This study has the potential to provide valuable insights into the therapeutic potential of molecular chaperones in AD. The results of this study may inform the development of new treatments that target the root cause of the disease. The use of engineered exosomes for targeted delivery of nucleic acid cargo represents a promising platform for AD treatment, and the study's focus on safety, tolerability, and initial proof-of-mechanism data will provide valuable insights into the potential of this therapeutic strategy.

Original Information Beyond the Obvious: While the study's focus on molecular chaperones and engineered exosomes is not entirely novel, the specific approach of using autologous dendritic cell-derived exosomes engineered with neuron-targeting peptides and DNAJB6 mRNA is an original aspect of this study. The use of a single intracisternal dose of NV-101 via a single intracisternal magna injection is also an innovative approach that warrants further investigation.

In summary, this study represents a significant step forward in AD research, with a novel therapeutic strategy that targets the root cause of the disease. The use of engineered exosomes for targeted delivery of nucleic acid cargo represents a promising platform for AD treatment, and the study's focus on safety, tolerability, and initial proof-of-mechanism data will provide valuable insights into the potential of this therapeutic strategy.

Read the original article on medRxiv

Analysis of the Significance, Importance, Timeliness, and Relevance of the Topic

The topic of adaptive deep brain stimulation (aDBS) versus conventional DBS (cDBS) in Parkinson's disease patients is significant, important, and timely. Parkinson's disease is a chronic and debilitating neurodegenerative disorder affecting millions worldwide, and deep brain stimulation (DBS) is a established treatment option for motor symptoms. However, the current standard of care, cDBS, has limitations, particularly in its reliance on fixed stimulation parameters. The potential of aDBS to modulate stimulation based on real-time biomarkers offers a promising approach to improving treatment outcomes.

Breakdown of the Text and Relationships between Items

  1. Background: The text sets the context for the study, highlighting the limitations of cDBS and the potential of aDBS to offer advantages. It also notes the inconclusive evidence on aDBS efficacy under chronic stimulation.
  2. Objective: The objective of the study is clearly stated, aiming to compare the efficacy of aDBS versus cDBS under chronic stimulation in Parkinson's disease patients.
  3. Methods: The text describes the study design, including the double-blind, randomized crossover trial, patient selection, and stimulation protocols. The use of a dual-threshold algorithm to adjust amplitude in response to subthalamic beta-band LFP power is a key aspect of aDBS.
  4. Results: The results show no statistically significant differences between aDBS and cDBS across primary outcomes. However, exploratory analyses reveal heterogeneous directional effects, with some outcomes favoring aDBS and others favoring cDBS.
  5. Conclusions: The study concludes that aDBS and cDBS show comparable efficacy across clinical outcomes under chronic stimulation with optimized medication. The findings suggest that baseline clinical characteristics of patients may shape the results of aDBS, warranting larger trials to identify patient subgroups who may benefit from each stimulation approach.

Usefulness of the Text for Disease Management and Drug Discovery

While the study does not provide original information beyond the obvious, it contributes to the growing body of evidence on aDBS efficacy. The findings have implications for the management of Parkinson's disease, suggesting that aDBS may be a viable treatment option for certain patient subgroups. However, the study's limitations, including the small sample size and short trial duration, highlight the need for further research to fully understand the potential of aDBS.

Originality of Information

The study's findings are consistent with existing literature on aDBS, and the results are not surprising given the small sample size and exploratory nature of the study. However, the study's methodology and analysis are rigorous, and the conclusions are well-supported by the data. The text does not provide any new or groundbreaking information but rather contributes to the cumulative knowledge on aDBS efficacy.

Comparison with the State of the Art

The study's findings are consistent with existing studies on aDBS efficacy, which have reported mixed results. However, the study's use of advanced analysis techniques, such as mixed-effects analysis of covariance, and its focus on exploratory analyses to examine treatment-by-baseline interactions are novel aspects of the study. The study's findings highlight the need for larger trials to identify patient subgroups who may benefit from each stimulation approach, which is a key area of ongoing research in the field.

In conclusion, the text provides a well-structured and informative analysis of the efficacy of aDBS versus cDBS in Parkinson's disease patients. While the study does not provide original information beyond the obvious, it contributes to the growing body of evidence on aDBS efficacy and has implications for the management of Parkinson's disease.

Read the original article on medRxiv

Analysis of the Text: Parkinson's Disease Research and the Australian Parkinson's Genetics Study

The provided text outlines the Australian Parkinson's Genetics Study (APGS), a nation-wide research initiative aimed at advancing our understanding of Parkinson's disease (PD). This analysis will examine the significance, importance, timeliness, and relevance of the topic, as well as the usefulness of the text for disease management and drug discovery.

Significance: Parkinson's disease is a complex neurodegenerative condition with a multifactorial etiology, affecting millions worldwide. Despite significant research efforts, the underlying causes and biological pathways of PD remain poorly understood. The APGS is a large-scale, nationwide initiative that seeks to address this knowledge gap by recruiting a large cohort of participants with PD and collecting comprehensive data on sociodemographic, clinical, environmental, lifestyle, and behavioural factors.

Importance: Understanding the determinants and progression of PD is crucial for developing effective prevention and treatment strategies. The APGS aims to provide insights into the genetic and environmental contributors to PD, which is essential for developing targeted therapeutic interventions. Additionally, the study's comprehensive design and ongoing expansion position it as a transformative platform for informing risk prediction, biomarker discovery, and therapeutic development for PD.

Timeliness: The APGS is an ongoing nationwide initiative, and its recruitment success highlights the effectiveness of innovative and cost-effective outreach strategies. This is particularly relevant in the context of current global health priorities, where there is an increasing need for large-scale, population-based studies to inform disease management and prevention strategies.

Relevance: The study's focus on PD is highly relevant, given the growing prevalence of the disease worldwide. The APGS's comprehensive design and ongoing expansion make it a valuable resource for researchers, clinicians, and policymakers seeking to understand the underlying causes and progression of PD.

Usefulness for Disease Management and Drug Discovery: The APGS has the potential to provide significant insights into the determinants and progression of PD, which can inform the development of effective prevention and treatment strategies. The study's comprehensive design and ongoing expansion position it as a transformative platform for:

  1. Risk prediction: By identifying genetic and environmental contributors to PD, the APGS can inform the development of targeted risk prediction models.
  2. Biomarker discovery: The study's comprehensive data collection and genomic profiling can identify novel biomarkers for PD diagnosis and monitoring.
  3. Therapeutic development: The APGS's insights into the underlying causes and progression of PD can inform the development of targeted therapeutic interventions.

Original Information: While the text does not reveal entirely new information, it provides a comprehensive overview of the APGS, highlighting its innovative design, recruitment strategies, and potential impact on PD research. The study's large-scale, nationwide approach and comprehensive data collection make it a valuable resource for researchers and clinicians.

Comparison with the State of Art: The APGS is one of the largest active PD cohorts globally, and its comprehensive design and ongoing expansion position it as a leading research initiative in the field. While there are other large PD cohorts, the APGS's innovative outreach strategies and cost-effective approach make it a valuable resource for researchers seeking to understand the underlying causes and progression of PD.

In conclusion, the text provides a comprehensive overview of the Australian Parkinson's Genetics Study, highlighting its significance, importance, timeliness, and relevance. The study's large-scale, nationwide approach and comprehensive data collection make it a valuable resource for researchers, clinicians, and policymakers seeking to understand the underlying causes and progression of Parkinson's disease.

Read the original article on medRxiv


Please, help us continue to provide valuable information: